Yingsheng Biology, a Chinese biotechnology firm that provides mass spectrometry (MS) services, announced on Wednesday that it has raised nearly RMB100 million (US$14.47 million) in a series C round of financing.
Chinese Biotech Firm Yingsheng Biology Gets $14M In Series C Round comes originally from China Money Network. All Rights Reserved.